Related posts

Consumer, housing data misses, stocks sinkWall Street edges up, Tesla beats3 Best U.S. Healthcare ETFs
Investor Insights

This summary was created by AI, based on 21 opinions in the last 12 months.

Stryker Corp. (SYK-N) is a highly regarded medical devices company with a strong focus on key areas such as artificial joints and specialized medical equipment. The company benefits from a significant backlog of surgeries due to Covid, and its innovative products and relationships with surgeons position it well for future growth, both domestically and internationally. Experts agree that Stryker has a great story, with a strong brand loyalty and a demographic tailwind supporting its compounding growth for the next several years. The company's strong fundamentals and solid growth, coupled with the potential for further acquisitions, make it a compelling choice for long-term healthcare investors.

Consensus
Bullish
Valuation
Fair Value
PAST TOP PICK
Stryker Corp.
(A Top Pick May 12/23, Up 15%)

Has since sold shares. Believes stock is fully valued. Medical device business performing well. Surgeries recovered after pause during Covid-19 pandemic. 

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Demographic tailwind. User loyalty. Most revenue comes from US. Global growth opportunities, especially in EM. Medical devices are really changing how people live. Covid backlog is being caught up. Tuck-on acquisitions. Yield is 0.9%.

(Analysts’ price target is $360.04)
biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Revenue: US (73%), developed world (19%), emerging markets (rest). Lots of good growth internationally. Demographic play. Strong brand loyalty. Free cash will be used for acquisitions. Great compounding story for the next several years. Yield is 0.9%.

(Analysts’ price target is $356.78)
biotechnology / pharmaceutical
COMMENT
Stryker Corp.

AI and weight-loss drugs are the two manias in the market now. SYK makes medical devices (hip and knee), but you must be below a certain weight to qualify for these operations.  The weight-loss drugs will open a greater market for SYK.

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Great story. Medical devices is a really important area of healthcare. Tremendous brand loyalty from end-user, plus a demographic play. Great operating margins and quarterly numbers, which will just keep on getting better. Lots of growth internationally. Yield is 0.9%.

(Analysts’ price target is $350.67)
biotechnology / pharmaceutical
BUY
Stryker Corp.

Medical devices are an important area that keeps people out of expensive hospitals, improves quality of life, and reduces reliance on drugs. Great advances, which will grow over the years. You want to be in this area. He owns SYK and JNJ in the space.

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Medical devices. Joint replacements. Huge backlog due to Covid. Costs increased from supply chains and labour, but now sorted out. Really improves quality of life. Great business, lots of growth from aging demographics. Lots of growth internationally, too. Once a doctor "buys in", tremendous brand loyalty. Yield is 1%.

(Analysts’ price target is $318.71)
biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

It is in the medical devices field producing parts for artificial knees, hips, etc. and improving patient quality of life. Surgeons tend to stick with the same products so there is a stability to its income. The backlog from Covid is being decreased but there is room to grow internationally and an aging population needs more of these surgeries. 72% of its business comes from the U.S. and the rest from emerging markets and the developed world. They have lots of free cash flow to buy other companies.       Buy 18  Hold 11  Sell 1

(Analysts’ price target is $314.49)
biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Doing well given the backlog in surgeries. 73% of their business is in the US, but there's growth in emerging markets where they also operate. Doctors stick with their products and seldom change. Also, aging demographics help. They could make acquisitions, which will benefit them.

(Analysts’ price target is $311.03)
biotechnology / pharmaceutical
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK
Stryker Corp.

Stryker has beaten three of its last four quarters, trades at 38.8x earnings, after scaling nearly 46x earlier this year and pays a modest 1.1% dividend. Its chart so far this year shows it trading in a range between $270 and $305, and shares dipped below $270 at the end of September. A trader or long-term investor could step in now.

biotechnology / pharmaceutical
HOLD
Stryker Corp.
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

SYK has performed well this year, increasing as much as 24% year-to-date and as high as 48% (before the recent sell-off) on a one-year basis. Its valuation reached its historical high point of ~5.5X forward sales and ~28X forward earnings. Its fundamentals are strong and it continues to expand on most metrics, but we feel that its valuation became too stretched and we're beginning to see its price decline alongside the broader US healthcare market. We would be comfortable continuing to hold this name as part of a long-term healthcare position. 
Unlock Premium - Try 5i Free

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Stryker makes replacement body parts with several components involved. There is a huge backlog of elective surgeries due to Covid. Also an aging population needs more of these artificial parts so there is lots of growth ahead. Surgeons tend to use the same parts rather than switching to other makes. It has a great balance sheet and may make more acquisitions to grow the business. There may be some cost issues to deal with but this shouldn't be a problem. 70% of its business comes from the U.S.             Buy 17  Hold 12  Sell 1

biotechnology / pharmaceutical
BUY
Stryker Corp.

Great business with aging population.
Bullish on healthcare sector.
Good time to buy for long term investor.
Strong fundamentals. 

biotechnology / pharmaceutical
BUY
Stryker Corp.

They just reported a good quarter. They have solid growth; there will be more surgeries through the backlog.

biotechnology / pharmaceutical
BUY
Stryker Corp.

Beneficiaries of increase in procedures since Covid. Replacement parts plus equipment. Never a cheap stock, but going into a growth period. Wouldn't hesitate to recommend it as part of a portfolio. Quality, well managed.

biotechnology / pharmaceutical
Showing 1 to 15 of 151 entries

Stryker Corp.(SYK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 8

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 9

Stockchase rating for Stryker Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stryker Corp.(SYK-N) Frequently Asked Questions

What is Stryker Corp. stock symbol?

Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N

Is Stryker Corp. a buy or a sell?

In the last year, 9 stock analysts published opinions about SYK-N. 8 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Stryker Corp..

Is Stryker Corp. a good investment or a top pick?

Stryker Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Stryker Corp..

Why is Stryker Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stryker Corp. worth watching?

9 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.

What is Stryker Corp. stock price?

On 2024-05-29, Stryker Corp. (SYK-N) stock closed at a price of $341.14.